Want to see VRCA full AI Analyst Report?
Verrica Pharmaceuticals (VRCA) Price & Analysis
VRCA Stock Chart & Stats
- Day’s Range
- $3.25 - $3.49
- 52-Week Range
- $3.25 - $9.82
- Previous Close
- $3.42
- Volume
- 76.83K
- Average Volume (3M)
- 49.82K
- Market Cap
- $57.55M
- Enterprise Value
- $121.00M
- Total Cash (Recent Filing)
- $11.20M
- Total Debt (Recent Filing)
- $1.81M
- Price to Earnings (P/E)
- ―
- Beta
- 1.75
- Next Earnings
- Nov 09, 2026
- EPS Estimate
- -0.5
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
YCANTH Commercial Traction
Rising dispensed units and product revenue indicate improving prescriber adoption and patient demand for YCANTH. Continued commercial traction can expand the company’s revenue base, strengthen channel relationships, and provide operating leverage as the product scales.
Strong Product Economics
A gross product margin above 90% provides attractive unit economics and leaves substantial contribution potential from incremental YCANTH sales. If maintained as volume grows, this margin profile can support commercial investment and help narrow losses over time.
Partner-funded Pipeline Expansion
Torii’s substantial trial funding reduces Verrica’s direct burden while advancing a potentially broader common-warts opportunity. Active enrollment and international participation also diversify the development pipeline and create additional long-term growth avenues beyond current YCANTH sales.
Bears Say
Persistent Operating Losses
The company’s high product margin has not yet translated into profitability because operating expenses remain well above the current revenue base. Continued losses constrain internally generated capital, increase dependence on financing, and make sustainable earnings growth dependent on substantial commercial scale.
Ongoing Cash Consumption
Persistent operating and free-cash-flow deficits mean Verrica is still consuming capital to fund commercialization and development. Until revenue growth materially offsets R&D and selling costs, the company may need additional external funding, limiting financial flexibility and increasing execution sensitivity.
Weakened Balance-sheet Cushion
The sharp reduction in equity leaves a smaller buffer against continued losses and future development spending. A thinner capital base reduces resilience if milestones or sales targets are delayed, and it increases the importance of securing financing on manageable terms.
Verrica Pharmaceuticals News
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
What is Verrica Pharmaceuticals’s market cap?
When is Verrica Pharmaceuticals’s upcoming earnings report date?
How were Verrica Pharmaceuticals’s earnings last quarter?
Is Verrica Pharmaceuticals overvalued?
Does Verrica Pharmaceuticals pay dividends?
What is Verrica Pharmaceuticals’s EPS estimate?
How many shares outstanding does Verrica Pharmaceuticals have?
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Verrica Pharmaceuticals Stock Smart Score
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jayson Rieger
- Employees
- 76
- Website
- www.verrica.com
- Address
- 44 West Gay Street Suite 400, West Chester, PA, 19380, US
Verrica Pharmaceuticals (VRCA) Earnings & Revenues
VRCA Earnings Call
Earnings Call SentimentNeutral
The call presents a mix of clear commercial momentum for YCANTH (robust unit growth, quarter-over-quarter revenue gains, new international distribution, and strong trial progress) and encouraging clinical signals (VP-315 Phase II abscopal effects and active Phase III enrollment for common warts). Offsetting these positives are sizable year-over-year revenue decline driven by last year’s one-time milestone, substantial GAAP and non-GAAP losses, materially higher R&D and SG&A expense, a legal settlement charge, and a relatively modest cash balance that makes the company reliant on a conditional credit facility. Management’s nondilutive financing and Torii’s substantial trial funding materially de-risk near-term liquidity and program funding, but financial outcomes remain contingent on milestone achievement, careful draw decisions, and successful trial readouts.
View all VRCA earnings summariesVRCA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |